The Phase 3 TRIUMPH-Outcomes entry, sponsored by Eli Lilly and Company, was last updated on 8 October 2026.
Bethesda, Maryland, 8 October 2026 — The ClinicalTrials.gov registry record with identifier NCT06383390, a Phase 3 interventional study sponsored by Eli Lilly and Company, was last updated on 8 October 2026 and carries the overall status active, not recruiting.
The registry returned 33 records in total for the search term retatrutide on the day this wire was pulled.
Source documents
-
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
- Identifier
- Registry identifier NCT06383390
- Registry status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Last update posted
- 2026-10-08